Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.77 |
| ▸ | NPC1 | O15118 | 5/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | CASP3 | P42574 | 1/20 | 0.72 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.72 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.72 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 9/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | XDH | P47989 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15679959 | 0.90 | RAB9A (0.81) | RAB9ASMN1; SMN2NPC1KDM4EPOLB | |
| SCHEMBL2069278 | 0.87 | RAB9A (1.00) | RAB9ASMN1; SMN2NPC1KDM4EPOLB | |
| SCHEMBL12475206 | 0.87 | SMN1; SMN2 (0.77) | RAB9ASMN1; SMN2NPC1KDM4EPOLB | |
| SCHEMBL28836113 | 0.87 | RAB9A (0.77) | RAB9ASMN1; SMN2NPC1KDM4EPOLB | |
| SCHEMBL3844047 | 0.86 | SMN1; SMN2 (0.75) | RAB9ASMN1; SMN2NPC1KDM4EPOLB | |
| SCHEMBL8341784 | 0.86 | SMN1; SMN2 (0.75) | RAB9ASMN1; SMN2NPC1KDM4EPOLB | |
| SCHEMBL15656858 | 0.85 | RAB9A (0.74) | RAB9ASMN1; SMN2NPC1KDM4EPOLB | |
| SCHEMBL13883748 | 0.84 | RAB9A (0.73) | RAB9ASMN1; SMN2NPC1KDM4EPOLB | |
| SCHEMBL15656341 | 0.84 | SMN1; SMN2 (0.73) | RAB9ASMN1; SMN2NPC1KDM4EPOLB | |
| SCHEMBL15654609 | 0.84 | RAB9A (0.72) | RAB9ASMN1; SMN2NPC1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114990587-B | Electrochemical synthesis method of thiazole compound | 华南理工大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-114990587-A | Electrochemical synthesis method of thiazole compound | 华南理工大学 | 2022-09-02 | — | — | CN | disclosed |
| EP-2594555-B1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA PHARM CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2594555-B1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA PHARM CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2594555-A1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594555-A1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-7439259-B2 | Thiazole derivatives for treating PPAR related disorders | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-21 | — | — | US | disclosed |
| WO-2008087367-A2 | SUBSTITUTED (PHENYLTHIAZOLYL)-PHENYL-PROPAN-1-ONE AND (PHENYLOXAZODYL)-PHENYL-PROPAN-1-ONE DERIVATIVES, PREPARATIONS AND USES OF SAME | GENFIT (FR) | 2008-07-24 | — | — | WO | disclosed |
| EP-1751149-A1 | BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS | ABBOTT LABORATORIES (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7098222-B2 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | ABBOTT LABORATORIES (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1651631-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC. (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050272728-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005113551-A1 | BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS | ABBOTT LABORATORIES (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050256118-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | ABBOTT LABORATORIES | 2005-11-17 | — | — | US | disclosed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005012288-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272728-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | HRH3, HRH4, HRH2 | RAB9A 1510/4885SMN1; SMN2 4497/4885NPC1 2861/4885 |
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | CDKN1A, SKP2, CCNI | RAB9A 2990/4885SMN1; SMN2 2696/4885NPC1 3743/4885 |
| US-20050256118-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | HRH3, HRH4, HRH2 | RAB9A 1510/4885SMN1; SMN2 4497/4885NPC1 2861/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | RAB9A 893/4885SMN1; SMN2 2019/4885NPC1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.